Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) clinical programs — 159 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Vertex Pharmaceuticals (Australia) projects

159 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 159 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

159 programs

Clinical programs

Page 3 of 4

  1. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial

  2. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  3. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    3 trials

  4. VX-787

    Vertex Pharmaceuticals (Australia) Pty.

    Influenza Virus

    phase 2 small molecule completed

    1 trial

  5. VX-814

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial

  6. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial

  7. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  8. VX-950

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    2 trials

  9. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    1 trial

  10. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  11. VX23-670-001

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  12. VX24-993-103

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  13. biricodar dicitrate

    Vertex Pharmaceuticals (Australia) Pty.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  14. telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule terminated

    1 trial

  15. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  16. 14C-VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  17. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial

  18. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial

  19. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  20. G060-A5

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  21. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  22. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial

  23. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  24. PegInterferon

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  25. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  26. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  27. Prednisone

    Vertex Pharmaceuticals (Australia) Pty.

    Drug Interactions

    phase 1 small molecule completed

    1 trial

  28. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  29. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  30. Telaprevir; Moxifloxacin; Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  31. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  32. VCH 916

    Vertex Pharmaceuticals (Australia) Pty.

    HCV Infection

    phase 1 small molecule completed

    1 trial

  33. VCH-222

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  34. VX-118

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  35. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial

  36. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  37. VX-272

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial

  38. VX-433

    Vertex Pharmaceuticals (Australia) Pty.

    Narcolepsy Type 1 (NT1)

    phase 1 small molecule active

    1 trial

  39. VX-440

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  40. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy

    phase 1 small molecule completed

    1 trial

  41. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    7 trials

  42. VX-581

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial

  43. VX-634

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  44. VX-668

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  45. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial

  46. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 1 small molecule completed

    1 trial

  47. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    In Development for Cystic Fibrosis

    phase 1 small molecule completed

    2 trials

  48. VX-828

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    2 trials

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

159 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.